Kidney disease proteome research
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Blood Plasma
DISEASE(S): Kidney Cancer
SUBMITTER: 
Anna Kaysheva
LAB HEAD: Anna Kaysheva
PROVIDER: PXD051799 | Pride | 2025-01-07
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| 230426_RNCL_S042.mgf | Mgf | |||
| 230426_RNCL_S042.raw.zip | Raw | |||
| 230426_RNCL_S042_IA_workflow.xml | Xml | |||
| 230426_RNCL_S096.mgf | Mgf | |||
| 230426_RNCL_S096.raw.zip | Raw |
Items per page: 5 1 - 5 of 222 |
Similar Datasets
Project description:The aim of the present study was the development of a relatively simple method without enrichment step to detect, in a mixture of peptides and phosphopeptides, a maximum of CPPs, including multi-phosphorylated and large-size CPPs, by using high pressure liquid chromatography (HPLC), high-resolution mass spectrometry (MS) and bioinformatics. A commercial casein hydrolysate was used as model hydrolysate for this purpose. This approach consisted of use of double and partial dephosphorylations of CPPs as well as digestion by EndoGluC protease before peptidomics analysis.
2021-09-29 | PXD027132 | Pride
Project description:This study aimed to identify and characterize bioactive peptides derived from protein hydrolysates of Arthrospira platensis (APPH) and Tetraselmis chuii (TCPH) using an integrated peptidomics and bioinformatics approach. Proteins extracted from the microalgae were hydrolyzed using pepsin (EC 3.4.23.1) at various enzyme/substrate (E/S) ratios. APPH and TCPH, prepared at an E/S ratio of 1/10 (w/w), were analyzed using peptidomics through reverse-phase high-performance liquid chromatography (RP-HPLC) coupled with tandem mass spectrometry (MS/MS). Using the UniProtKB database, a total of 265 unique peptides were identified, including 187 peptides from APPH and 78 peptides from TCPH. Subsequent in silico analysis of these peptides revealed favorable physicochemical properties, with a notable distribution of hydrophobic (APPH: 26; TCPH: 5), amphipathic (APPH: 70; TCPH: 16), and hydrophilic peptides (APPH: 59; TCPH: 17). Toxicity assessments confirmed that none of the peptides showed hemolytic or cytotoxic risks, except for one peptide identified in TCPH with potential cytotoxicity. Furthermore, bioactivity predictions demonstrated significant multifunctional properties (scores exceeding the 0.500 threshold), identifying peptides with antihypertensive (APPH: 2; TCPH: 1), anti-diabetic (APPH: 2), anti-inflammatory (APPH: 14; TCPH: 5) and antimicrobial (APPH: 7) activities. The current study thus establishes protein hydrolysates from A. platensis and T. chuii as promising sources of bioactive peptides suitable for nutraceutical applications. Our integrated analytical and computational strategy provides critical insights into peptide multifunctionality, supporting further research and development of microalgae-derived peptides.
2025-07-09 | PXD058907 | Pride
Project description:Adaptive evolution experiment for enhaced tolerance to hydrolysates of lignocellulosic biomass in S. cerevisiae. The samples involves a batch culture in YNB and Hydrolysates. Cells were harvested at mid-exponential phase. Three biological replicas of 8 samples vs reference Samples 1-8 are the first replicate, Samples 9-16 are the second replicate, Samples 17-24 are the third replicate.
2013-04-26 | E-GEOD-44085 | biostudies-arrayexpress
Project description:Insertion of lipopolysaccharide (LPS) into the outer membrane (OM) of Gram-negative bacteria is mediated by a druggable OM translocon consisting of a beta-barrel membrane protein, LptD, and a lipoprotein, LptE. The beta-barrel assembly machinery (BAM) assembles LptD together with LptE to form a plug-and-barrel structure. In the enterobacterium Escherichia coli, formation of two native disulfide bonds in LptD controls LPS translocon activation. Here we report the discovery of LptM (formerly YifL), a conserved lipoprotein that assembles together with LptD and LptE at the BAM complex. We demonstrate that LptM stabilizes a conformation of LptD that can efficiently acquire native disulfide bonds and be released as mature LPS translocon by the BAM complex. Inactivation of LptM causes the accumulation of non-natively oxidized LptD, making disulfide bond isomerization by DsbC become essential for viability. Our structural prediction and biochemical analyses indicate that LptM binds to sites in both LptD and LptE that are proposed to coordinate LPS insertion into the OM. These results suggest that, by mimicking LPS binding, LptM facilitates oxidative maturation of LptD, thereby activating the LPS translocon.
2023-10-11 | PXD041774 | Pride
Project description:Increased export of transglutaminase-2 (TG2) by tubular epithelial cells (TECs) into the surrounding interstitium modifies the extracellular homeostatic balance leading to fibrotic membrane expansion. Although silencing of extracellular TG2 ameliorates progressive kidney scarring in animal models of chronic kidney disease, the pathway through which TG2 is secreted from TECs and contributes to disease progression has not been elucidated. In this study, we developed a global proteomic approach to identify binding partners of TG2 responsible for TG2 externalization in kidneys subjected to unilateral ureteric obstruction, using TG2-knockout kidneys as negative controls. We report a robust and unbiased analysis of the membrane interactome of TG2 in fibrotic kidneys relative to the entire proteome post-UUO detected by SWATH-mass spectrometry.
2018-02-07 | PXD008173 | Pride
Project description:In stable renal transplant recipients with hyperparathyroidism, the vitamin D agonist paricalcitol reduces the level of proteinuria. Animal studies have indicated possible anti-fibrotic and anti-inflammatory effects of paricalcitol. We hypothesised that early introduction of paricalcitol in de novo renal transplant recipients would reduce proteinuria and counteract development of fibrosis in the allograft. A single centre, prospective, randomized, open label trial investigating the additional effect of paricalcitol 2ug/day to standard care was performed. Participants were included 8 weeks after engraftment irrespective of PTH-level and followed for 44 weeks. Microarray analyses were performed in kidney biopsies at study end for the investigation of potential effects on gene expression profile. This dataset is part of the TransQST collection.
2017-09-01 | E-GEOD-83486 | biostudies-arrayexpress
Project description:Identification of common Leishmania antigen proteins is important for practical purposes ranging from diagnostic to the development of a vaccine for the prevention of leishmaniasis. Moreover, we need to establish the potential drug targets that interrupt the replication and transmission of the pathogen to promote drug discovery. Therefore, the objective of this work was to provide the public proteome database which would be useful for the establishment of novel protein antigenicity for therapeutic purposes. This information would introduce the alternative protein targets for Leishmaniasis, allowing the development of therapeutic strategies for the disease.
2022-05-20 | PXD026304 | Pride
Project description:In this study, investigators recruited the largest reported cohort of tolerant kidney transplant recipients who maintained their graft after ceasing to take their immunosuppression drug, and compared this cohort to subjects with stable allograft function while on immunosuppression and healthy non transplated, controls. Using gene expression studies, they identified genetic markers that are strong candidates for predicting kidney transplant candidates who may benefit from minimization or withdrawl of immunosuppression. Microarrays were used to detect expressed gene profiles of whole-blood total RNA from subjects in the tolerant, standard immunotherapy and healthy control participants Total of 19 Tolerant (TOL) participants, 27 Standard Immunotherapy (SI) participants, and 12 Healthy Controls (HC)
2010-06-16 | E-GEOD-22229 | biostudies-arrayexpress
Project description:Rationale There is a need for new and better biomarkers for hypertrophic cardiomyopathy (HCM) which correlate more closely with disease progression as determined by clinical imaging and biohumoral information. We have used a combination of heart tissue and plasma proteomics to identify potential biomarkers for HCM and developed them into an exploratory targeted proteomic assay. Objective To identify informative staging biomarkers for HCM and develop them into a blood test. The test using 10 µl of plasma, was developed into a 10 min liquid chromatography-tandem/mass spectrometry (LC-MS/MS) assay to analyze multiple candidate biomarkers and evaluate their association with clinical phenotypes in patients with HCM. Methods and Results Myocardial tissue and plasma samples from patients with HCM and healthy volunteers (controls) were screened using a combined gel- and nano-LC quadrupole time of flight MS approach. Twenty-six potential biomarkers were identified from the proteomics screens and developed into a multiplexed targeted proteomic assay. Their association with clinical phenotypes was tested in plasma samples collected from 207 prospectively recruited participants: 110 patients with HCM (50.1 ± 15.0 years, 70% male; 48 [44%] with identified genetic mutations) and 97 controls (49.6 ± 13.4 years, 58% male), randomly split into training (80 HCM, 67 controls) and validation datasets (30 HCM, 30 controls). Six markers (Aldolase Fructose-Bisphosphate A, Complement C3, Glutathione S-Transferase Omega 1, Ras Suppressor Protein 1, Talin 1, and Thrombospondin 1) were significantly increased (P<0.006) in the plasma of HCM patients compared to controls in the training dataset. These markers correlated with left ventricular (LV) wall thickness, LV mass and % myocardial scar on cardiovascular magnetic resonance imaging. Using supervized machine learning (ML) this panel differentiated HCM from controls (area under the curve: 0.89 in the training dataset, sensitivity 96%, 95% confidence interval [CI] 77–93; specificity 87%, 95%CI 77–94; and 0.87 in the validation dataset, sensitivity 97%, 95%CI 83–100; specificity 77%, 95%CI 58–90). Four of the biomarkers as well as the composite ML score of the plasma proteome correlated with the presence of nonsustained ventricular tachycardia and the estimated 5-year risk of sudden cardiac death. Conclusion By developing a high-throughput, multiplex, and targeted proteomic plasma assay we identified 6 biomarkers that correlate with the presence of disease and with clinical risk score for sudden cardiac death.
2019-07-08 | PXD009859 | Pride
Project description:RIVUR Trial participants had Agilent 1M probe and or Nimblegen 2.1M probe aCGH performed on genomic DNA. The study was designed to discover DNA copy number variations in genes critical in kidney/urinary tract development and urinary tract infection susceptibility. Reference DNA used is a single male sample
2019-04-15 | E-MTAB-7890 | biostudies-arrayexpress